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CASE PRESENTATION
A 62-year-old woman on chronic ambulatory peritoneal
dialysis (CAPD) for end-stage renal disease, presumed
secondary to type II diabetes mellitus and hypertension,
presented to the emergency department with nausea,
vomiting, and abdominal pain with no localizing features.
Five months before the current admission, the patient
started experiencing recurrent fevers, but on physical
examination no obvious primary source could be
identified. Several peritoneal dialysate samples were sent,
but they were found persistently negative for bacterial
and mycobacterial pathogens. Work-up for fever of
unknown origin was significant for the following:
computed tomography scan of chest showed multiple
small lung nodules along with mild bilateral hilar
adenopathy. Mediastinoscopy-guided hilar lymph node
biopsy was unsuccessful owing to anterior mediastinal
fibrosis. Multiple induced sputum specimens and
bronchoalveolar lavage were negative for AFB stain and
culture. Repeat purified protein derivative skin test for
tuberculosis (TB) was negative. She was then empirically
treated with vancomycin and ceftazidime intraperitonealy
with no significant improvement. Three months before
current admission, she developed morning stiffness and
severe bilateral shoulder, thigh, and hip pains. Owing to
lack of response to intra-articular steroid injections and on
the basis of strong suspicion of polymyalgia rheumatica,
the patient’s rheumatologist started her on empirical
prednisone (10 mg) therapy.
Past medical history was significant for a positive
response to purified protein derivative skin test 30 years
ago, with no clinical evidence of TB at that time. She was
never given anti-tuberculous prophylaxis. Social history
was remarkable for Haitian origin by birth and having
immigrated to the United States of America 30 years ago.
Her peritoneal dialysis (PD) treatment over the past 5 years
was generally uneventful except for two past episodes of
bacterial peritonitis, which fully resolved on both occa-
sions with appropriate intraperitoneal antibacterial treat-
ment.
Physical examination on the current admission was
remarkable for fever of 103 F, heart rate 121/min; blood
pressure 164/72. The remainder of the examination was
unremarkable except for diffuse tenderness on palpation
of the abdomen. There was no guarding or rebound.
Bowel sounds were present.
Laboratory data: During this admission, initial
peritoneal dialysate cell count showed 806 white blood
cells, and 95% of the cells were polymorphonuclear cells.
Gram stain and cultures of the peritoneal fluid were sent,
which were subsequently noted to be negative for
bacterial and mycobacterial pathogens. Chest and
abdomen X-rays were unremarkable.
Acute surgical pathology was ruled out. For suspected
PD-associated bacterial peritonitis, she was initiated on
empiric intraperitoneal vancomycin and ceftazidime
treatment. Owing to lack of response to empiric
broad-spectrum antibacterial treatment, a decision was
made to remove PD catheter and to switch her to
hemodialysis. At the time of PD catheter removal,
laparoscopic visualization of peritoneum was normal and
peritoneal biopsy was obtained to rule out TB. The PD
catheter tip and peritoneal tissue culture grew acid-fast
organisms. This diagnosis was confirmed by DNA. An
RNA probe technique by polymerase chain reaction
demonstrated mycobacterium TB.
CLINICAL DIAGNOSIS
TB peritonitis.
FOLLOW-UP
The patient was started on antituberculous drug treatment
with rifampicin 600 mg q.d., isoniazid 300 mg q.d., pyrazi-
namide 1500 mg q.o.d., and ethambutol 1200 mg q. 48 h after
hemodialysis and moxifloxacin. She initially felt systemically
better. However, over the next month, the patient continued
to deteriorate with ongoing fevers and died of acute hypo-
xemic respiratory failure of unknown etiology and sepsis.
This case illustrates the perplexing diagnostic and
therapeutic problem of TB peritonitis in peritoneal dialysis
patients. In spite of the advances made in the chemotherapy
of mycobacterial infections, this condition carries a high
mortality, which may reflect the diagnostic delay that is often
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encountered in the already immunocompromised and the
malnourished PD patients. In other words, there is a race
against time.
DISCUSSION
Patients on maintenance dialysis are at higher risk of
acquiring mycobacterial infections than the general popula-
tion. The incidence of this condition varies widely among
different ethnic groups. The incidence of TB peritonitis
among dialysis patients in Europe and North America was
reported to be comparatively low (1–6%) in the literature
quoted.1,2 This compares with an incidence of up to 13% in
patients who are living in or emigrated from endemic areas
like the Indian subcontinent.
Other infectious causes of culture-positive peritonitis in
CAPD patients3 include Gram-positive aerobes (57.1%) most
commonly, staphylococcus epidermidis, Gram-negative aero-
bes (33.2%), yeast (2.6%), anaerobes (2.6%), and other
infections (4.5%). Whereas in patients not on peritoneal
dialysis, Escherichia coli and Bacteroides fragilis are the
predominant cause of peritonitis followed by Gram-positive
bacterial infections and candida species.4 Moore et al.,5 in
their study in England and Wales, observed that the incidence
of TB in dialysis patients is 100-fold greater than the inci-
dence in general population. Peritoneal TB, otherwise relatively
uncommon, has emerged as an important presentation of this
disease among PD patients.
Immune system in PD patients
Patients with chronic renal impairment and maintenance
dialysis patients are shown to have decreased systemic cellular
immunity.6,7 Morever, PD patients also have a compromised
local immune system that favors reactivation of TB in the
peritoneal cavity. Peritoneal macrophages, mesothelial cells,
and peritoneal lymphocytes form the main line of defense
against invading pathogens. Dialysis fluid dilutes the
peritoneal macrophage and lymphocyte concentrations and
minimizes their interaction with the antigens. The dialysate
milieu of a low pH, high lactate, and high glucose
concentration of the dialysis fluid results in a profound
impairment of bacterial phagocytosis, a blunted respiratory
burst response, and a strong inhibition to cytokine response,
which are undoubtedly detrimental to the peritoneal defense
system.8
TB peritonitis occurs most commonly following reactiva-
tion of latent tuberculous foci in the peritoneum that were
established from hematogenous spread from a primary lung
focus.9 It can also occur via hematogenous spread from active
pulmonary or miliary TB. Much less frequently, the
organisms enter the peritoneal cavity transmurally from an
infected small intestine or contiguously from tuberculous
salpingitis.
Clinical presentation and work-up
In addition to the cloudy PD effluent, either one or the
combination of fever, night sweats, anorexia, weight loss, and
abdominal pain may occur. Many case series10 have high-
lighted that fever will almost be invariably be present in this
condition, whereas it is not a common feature in bacterial
peritonitis. Talwani et al.,11 in their case series of 52 patients
with CAPD-associated tuberculous peritonitis, noted that
fever was present in 78%, abdominal pain in 92%, and
cloudy dialysate in 90% of the cases. Pulmonary disease is
generally not clinically detectable. Extra abdominal involve-
ment is rarely seen at presentation.
In a significant majority of patients and as seen in our
patient, the clinical presentation can be indistinguishable
from non-mycobacterial PD peritonitis. Every effort should
be made to rule out TB peritonitis in patients with prolonged
failure to thrive or relapsing peritonitis with negative
bacterial cultures and in febrile patients with non-resolving
peritonitis.
The work-up of patient with peritonitis (see Table 1)
begins with a peritoneal dialysate cell count and its
differential. However, the peritoneal dialysate cell count
should not be solely used to differentiate TB peritonitis from
other forms of peritonitis. Most cases of mycobacterial
peritonitis have a predominance of polymorphonuclear white
blood cells, similar to bacterial peritonitis. Indeed, patients
with neutrophilic peritonitis with no response to antibacter-
ial medications should also be investigated for TB. Notably,
certain case series have reported a predominance of
lymphocytic peritonitis, which should immediately trigger
the suspicion for TB peritonitis.10,12 Talwani et al.,11 in their
case series, noted that peritoneal dialysate cell count in 41
CAPD patients with culture-proven TB peritonitis 76% had
polymorphonuclear predominance, 12% had lymphocytic
predominance, and in the rest 12%, it was variable. Although
Gram staining of the peritoneal dialysate is considered central
to the work-up, it is frequently negative even among patients
with an established bacterial peritonitis. However, the
sensitivity of the smear examination by acid-fast staining
may be enhanced by centrifuging 100–150 ml of the dialysate
sample and the smear prepared from the pellet. Even then,
the reported sensitivity is disappointingly very low.13 A
specific diagnosis can be made by culturing the centrifuged
sediment using a solid medium (such as Lowenstein–Jensen
agar) and a fluid medium (Septi-chek, BACTEC; Becton
Dickinson; etc). The time of detection is considerably
decreased in fluid medium. However, the utility of cultures
is even more questionable considering the delay of 4–6 weeks
before a result is obtained. In most cases, the diagnosis is
made only after the demonstration of mycobacterium in
smears or culture (by then, it could be very late) or on
finding caeseating granulomata in the biopsy material.
Skin test, which identifies previous exposure to tubercu-
lous bacillus, may be useful in raising the suspicion of this
illness. However, it is shown that uremia impairs cell-
mediated immunity and is known to cause anergy to skin
testing, so a negative test should be interpreted with caution.
A positive test in a previously unimmunized individual
suggests exposure to TB. With the standard Mantoux skin
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test, any dialysis patient with at least 10 mm induration
48–72 h after intradermal injection should be considered
infected. Patients with X-ray evidence of healed TB or in
close contact with patients known to be infected with TB,
even 5 mm induration, should be considered positive.
A chest X-ray may show evidence of TB in some patients,
although features of active TB are much less common. Other
imaging tests that can be considered include an abdominal
ultrasound and computed tomography imaging – either
may reveal peritoneal thickening, lesions, and lymphadeno-
pathy.
For rapid diagnosis and high diagnostic yield, direct
visualization and targeted biopsy of the peritoneum by
laparoscopy or mini-laparotomy should be considered.12 In
typical cases, the visceral and parietal peritoneum is studded
with multiple whitish nodules of tubercles. Targeted biopsies
reveal granulomas in 100% of the patients and are positive
for acid-fast bacilli in 74% of the patients.14
Several DNA probes have also been developed for rapid
and specific identification of Mycobacterium tuberculosis.
These methods when used along with newer early methods of
detection of the growth (such as BACTEC, Septi-chek) can
establish the diagnosis in 1 or 2 days. Polymerase chain
reaction assays, which amplify mycobacterial 16S ribosomal
RNA, represent the ultimate in sensitivity, and under optimal
conditions are expected to detect even 1–10 organisms. Lye
et al.15 have successfully used this technique in the rapid
diagnosis of TB bacillus in peritoneal dialysate of patients
with PD peritonitis. However, the validity of this procedure
in PD patients has yet to be well established.
Treatment and prophylaxis
The International Society of Peritoneal Dialysis13 recom-
mends quadruple drug treatment with isoniazid, rifampicin,
pyrazinamide, and ofloxacin for established cases. An
unadjusted dose of isoniazid (5–6 mg/kg or 300 mg) should
be prescribed in dialysis patients. As well, the rifampicin
dose, if taken orally, does not require reduction below
600 mg/day. A recent study16 showed that rifampicin dialysis
fluid levels are quiet low owing to its high molecular weight,
high protein-binding capacity, and lipid solubility. Therefore,
rifampicin may need to be given via the intraperitoneal route.
Pyrazinamide dose should be adjusted for renal function.
Treatment with pyrazinamide and ofloxacin should be
stopped after 3 months; rifampicin and isoniazid should be
continued for a total of 12 months. Pyridoxine (50–100 mg)
should be given daily to avoid isoniazid-induced neurotoxi-
city. Ethambutol and streptomycin are not generally
recommended because of the risk of optic neuritis and
ototoxicity, particularly with prolonged use.
There is divided opinion on the need for the removal of
the PD catheter. Although most favor removal of the catheter
and reinsertion after 6 weeks of anti-tubercular treatment,
there are some case series that report successful treatment of
this condition without catheter removal. Early diagnosis and
appropriate therapy would help in the preservation of the
peritoneal integrity and long-term continuation of PD.
In the case series11,17 published, the short-term (attribu-
table) mortality of tuberculous peritonitis in PD patients was
observed to be 15–20%. This observed mortality rate is
greater than the B7% seen with tuberculous peritonitis
Table 1 | The common symptoms along with other features that should raise the concern of TB peritonitis, its diagnostic
approach, and the need for early initiation of anti-tuberculous therapy
Common presenting features
Fever (in most cases compared to bacterial peritonitis)
Abdominal pain and cloudy dialyzate
Peritoneal dialyzate cell count (WBC4100/mm3)
Neutrophilic predominance (commonest presentation)
Lymphocytic predominence (less common but very suggestive)
Variable differential count (less common)
Acid-fast staining of centrifuged dialyzate
(Rarely diagnostic) and negative Gram stain and bacterial culture
Other features suggestive of mycobacterial peritonitis
History of prolonged failure to thrive
Febrile patient with unresolving peritonitis
Relapsing peritonitis with negative bacterial culture
Previous history of TB or exposure to TB
High index of suspicion (if so, proceed with the below)
Skin tests
CXR
CT abdomen
Rapid TB culture techniques Molecular probe techniques Peritoneal visualization and biopsy
Timely initiation of anti-tuberculous therapy is the key
CT, computed tomography; CXR, chest X-ray; TB, tuberculosis; WBC, white blood cell.
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without CAPD.18,19 The only statistically significant variable
predicting death owing to TB was treatment delay. On
average, patients who had a treatment delay of 4 weeks since
the onset of symptoms eventually died of TB than unrelated
causes.11 With earlier diagnosis and timely initiation of
anti-tuberculous chemotherapy regimen based on suscept-
ibility findings, tuberculous peritonitis complicating PD can
be successfully treated with low mortality and without com-
promising the dialysis capacity of the peritoneal membrane.20
In light of the high incidence, mortality, and morbidity of
this disease, TB prophylaxis in chronically dialyzed patients is
worthy of consideration. At the very least, any dialyzed
patient with a positive tuberculin skin test, who lives in or has
migrated from an endemic area, has had close contact with
any patient with active pulmonary TB, is a recent tuberculin
converter, or has old X-ray evidence of healed TB should
receive isoniazid prophylaxis.
CONCLUSION
This case illustrates the diagnostic perplexity in diagnosing TB
peritonitis and its associated high mortality in the PD
population. A high degree of suspicion and an aggressive
diagnostic approach (including laparoscopic visualization and
peritoneal biopsy) should be applied to the patient with
persistent culture-negative peritonitis or any febrile patient
with non-resolving peritonitis. Molecular diagnostic tools with
the promise of ultimate efficiency, sensitivity, and rapidity,
with which they diagnose this condition, should be exploited
in combination with other diagnostic aids. In the very high-
risk population, TB prophylaxis should be considered.
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